Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will report third quarter 2025 financial results on Wednesday, November 12, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Investors must register in advance to receive dial-in numbers and PIN; the live webcast link will be provided and an archived webcast will be available for at least 30 days in the Investors section of the company website.
Acumen Pharmaceuticals (NASDAQ: ABOS) ha annunciato che riferirà i risultati finanziari del terzo trimestre 2025 il mercoledì 12 novembre 2025. La società organizzerà una conference call e una trasmissione audio in diretta alle ore 8:00 ET per fornire un aggiornamento sull'andamento aziendale e finanziario.
Gli investitori devono registrarsi in anticipo per ricevere i codici di accesso e il PIN; sarà fornito il link per la trasmissione in diretta e una versione registrata della webcast sarà disponibile per almeno 30 giorni nella sezione Investitori del sito web dell'azienda.
Acumen Pharmaceuticals (NASDAQ: ABOS) anunció que reportará los resultados financieros del tercer trimestre de 2025 el miércoles 12 de noviembre de 2025. La empresa organizará una llamada de conferencia y una transmisión de audio en directo a las 8:00 a.m. ET para proporcionar una actualización comercial y financiera.
Los inversionistas deben registrarse por adelantado para recibir números de marcación y PIN; se proporcionará el enlace de la transmisión en vivo y habrá una transmisión grabada disponible durante al menos 30 días en la sección de Inversionistas del sitio web de la empresa.
Acumen Pharmaceuticals (NASDAQ: ABOS)은 2025년 3분기 재무 실적을 2025년 11월 12일 수요일에 발표할 것이라고 발표했습니다. 회사는 비즈니스 및 재무 업데이트를 제공하기 위해 동부 표준시 기준 오전 8:00에 컨퍼런스 콜과 라이브 오디오 웹캐스트를 진행합니다.
투자자들은 다이얼 인 번호와 PIN을 받기 위해 사전에 등록해야 합니다; 라이브 웹캐스트 링크가 제공되며 최소 30일 동안 회사 웹사이트의 투자자 섹션에서 보관된 웹캐스트를 이용할 수 있습니다.
Acumen Pharmaceuticals (NASDAQ: ABOS) a annoncé qu'il publiera les résultats financiers du troisième trimestre 2025 le mercredi 12 novembre 2025. La société organisera une conférence téléphonique et une diffusion audio en direct à 8 h 00 HE pour fournir une mise à jour commerciale et financière.
Les investisseurs doivent s'inscrire à l'avance pour recevoir les numéros d'accès et le code PIN; le lien de diffusion en direct sera fourni et une diffusion en différé sera disponible pendant au moins 30 jours dans la section Investisseurs du site Web de l'entreprise.
Acumen Pharmaceuticals (NASDAQ: ABOS) gab bekannt, dass es die Drittquartalsberichte 2025 am Mittwoch, den 12. November 2025 veröffentlichen wird. Das Unternehmen wird eine Konferenzschaltung und eine Live-Audio-Übertragung um 8:00 Uhr Eastern Time abhalten, um ein Geschäfts- und Finanzupdate bereitzustellen.
Investoren müssen sich im Voraus registrieren, um Dial-in-Nummern und PIN zu erhalten; der Link zur Live-Webcast wird bereitgestellt und eine archivierte Webcast wird mindestens 30 Tage im Bereich Investoren der Firmenwebsite verfügbar sein.
Acumen Pharmaceuticals (NASDAQ: ABOS) أعلنت أنها ستعلن عن نتائج الربع الثالث 2025 في الأربعاء 12 نوفمبر 2025. ستعقد الشركة مكالمة مؤتمر وويب كاست صوتي مباشر في الساعة 8:00 صباحاً بتوقيت شرق الولايات لتقديم تحديث تجاري ومالي.
يجب على المستثمرين التسجيل مسبقاً للحصول على أرقام الاتصال ورمز PIN؛ سيتم توفير رابط البث المباشر وسيكون هناك بث مسجل متاح لمدة لا تقل عن 30 يوماً في قسم المستثمرين على موقع الشركة الإلكتروني.
- None.
- None.
NEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter 2025 financial results on Wednesday, November 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When will Acumen Pharmaceuticals (ABOS) report Q3 2025 results?
What time is the Acumen (ABOS) Q3 2025 earnings call and webcast?
How do I join the Acumen (ABOS) November 12, 2025 conference call?
Will Acumen (ABOS) provide a replay of the November 12, 2025 webcast?
Where can investors find the Acumen (ABOS) webcast link and archive?
